Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MGM$28.68-0.15(-0.54%)BetMGM Marks 100 Days in Alberta[9:52:11 AM ET]CACI$679.83+5.46(+0.81%)CACI's Good Dogs for Great Americans Reaches $50K Milestone to Fund First Veteran-Service Dog Team CACI International Inc (NYSE: CACI) today announced a milestone for its Good Dogs for Great Americans philanthropy program. Through this partnership...[9:45:00 AM ET]GXLDF$0.200.00(0.00%)Hi-View Resources Inc. to Attend the 52nd Annual New Orleans Investment Conference[9:30:00 AM ET]UBAB$62.000.00(0.00%)United Bancorporation of Alabama, Inc. Announces Third Quarter Results (OTCQX: UBAB) - United Bancorporation of Alabama, Inc. reported net income of $16.0 million for the nine months ended September 30, 2026, compared to ...[9:30:00 AM ET]DNLI$19.13-0.19(-0.98%)Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product[9:30:00 AM ET]KVHI$7.83+0.05(+0.64%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-9.39%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]TRNO$65.79+0.07(+0.11%)Terreno Realty Corporation Acquires Property in San Carlos, CA for $29.0 Million[9:15:00 AM ET]VIVK$1.06-0.44(-29.33%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.000.00(0.00%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.29%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]

MBRX · NASDAQ

Moleculin Biotech, Inc.

$8.94 +0.12 (+1.41%)

Company overview

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in a Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp. z.o.o. Moleculin Biotech, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$9.1M
Employees
17
Headquarters
Houston, TX
Website
moleculin.com
CEO
Walter V. Klemp
Listed
June 2, 2016
P/E
-0.32
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$37,000
Operating income
-$27M
EBITDA
-$28.9M
Net income
-$30.3M
EPS
-$27.96
Total assets
$23.4M
Total debt
$185,000
Earnings yield
-312.75%

Price chart

-0.242.485.207.9210.64
MBRX 1D NASDAQ O8.55H8.82L8.08C8.82+0.07 (+0.81%)Vol8.10K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
MBRXMoleculin Biotech, Inc. Press release Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 GlobeNewswire
MBRXMoleculin Biotech, Inc. Press release Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial GlobeNewswire
MBRXMoleculin Biotech, Inc. Press release Moleculin Announces Reverse Stock Split GlobeNewswire
MBRXMoleculin Biotech, Inc. Press release Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand GlobeNewsWire
MBRXMoleculin Biotech, Inc. Stock news Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell? Defense World
MBRXMoleculin Biotech, Inc. Press release Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference GlobeNewsWire
MBRXMoleculin Biotech, Inc. Stock news Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why Zacks Investment Research
MBRXMoleculin Biotech, Inc. Press release Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial GlobeNewsWire
MBRXMoleculin Biotech, Inc. Stock news Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment Globe News Wire
MBRXMoleculin Biotech, Inc. Press release Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment Globe News Wire
MBRXMoleculin Biotech, Inc. Press release Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment GlobeNewsWire
MBRXMoleculin Biotech, Inc. Press release Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits GlobeNewsWire
See more
FAQ

Questions about Moleculin Biotech, Inc.

What does Moleculin Biotech, Inc. do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in a Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp. z.o.o. Moleculin Biotech, Inc.
What is MBRX's market cap?
Moleculin Biotech, Inc. (MBRX) is a listed stock with a live quote. The latest market cap on this page is $9.1M.
Where is Moleculin Biotech, Inc. headquartered?
Moleculin Biotech, Inc. is headquartered in Houston, TX.
How do I get MBRX news from the API?
Call GET /v1/news?tickers=MBRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does MBRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MBRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the MBRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs